[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

888-662-6728 (U.S. Only)

Email address

global-roche-genentech-trials@gene.com

Condition

Multiple Myeloma

Treatment type

Interventional

Investigational product

Cevostamab

Phase

Phase 1

Sponsor

Genentech, Inc.

ClinicalTrials.gov identifier

NCT05646836

Study number

GO43980

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  2. Life expectancy of at least 12 weeks
  3. Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody.
  4. Documented evidence of progressive disease on or after the last prior therapy, or participants who were intolerant to the last prior therapy.
  5. Measurable disease, as defined by the protocol
  6. Participants agree to follow contraception or abstinence requirements as defined in the protocol
Exclusion criteria

  1. Any anti-cancer therapy within 3 weeks prior to initiation of study treatment with exception defined by the protocol
  2. Participants with autologous stem cell transplantation (SCT) within 100 days prior to first dose of study treatment
  3. Participants with prior allogeneic SCT or solid organ transplantation
  4. Active or history of autoimmune disease
  5. Participants with current or history of Central Nervous System (CNS) disease, or current CNS involvement by Multiple Myeloma (MM)
  6. Significant cardiovascular disease
  7. Participants with known clinically significant liver disease
  8. Symptomatic active pulmonary disease requiring supplemental oxygen
  9. Known active infection requiring intravenous anti-microbial therapy within 14 days prior to first study drug administration
  10. Other protocol defined inclusion/exclusion criteria may apply

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site